All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Uma Borate from Knight Cancer Institute Oregon Health & Science University, Portland, US, discusses new targeted therapies for acute myeloid leukemia (AML) including venetoclax in combination with azacitidine, ivosidenib, and enasidenib.
Impact of targeted therapy on treatment of AML
Editorial theme | Novel combination therapies using targeted agents
This article provides a summary of content relating to novel agent-containing combinations to date & introduces the new editorial theme of ‘Novel combination therapies using...
EHA 2019 | Which research areas hold promise for future treatments for AML?
Isolda Fernandez discusses research areas holding promise for future treatments for acute myeloid leukemia (AML) with the AML Global Portal at EHA 2019, Amsterdam, NL.
Subscribe to get the best content related to AML delivered to your inbox